Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

Gilead Sciences stock weighs Livdelzi data against regulatory hurdles

Clinical trial results Regulatory approval AI-generated analysis

πŸ“ˆ Gilead Sciences reported strong Phase 3 IDEAL results showing 75.4% of patients achieved alkaline phosphatase normalization at Week 52 versus 16.1% on placebo.

πŸ”¬ The study enrolled 96 adults with primary biliary cholangitis who had inadequate control or could not tolerate ursodeoxycholic acid treatment.

⚑ Treatment effect appeared early with 52.3% of participants reaching the composite endpoint after one month compared to 6.5% in the placebo group.

πŸ›‘οΈ Safety profile remained consistent with earlier studies, with serious adverse events occurring in only 3.1% of Livdelzi participants versus 12.9% on placebo.

πŸ—£οΈ Gilead plans discussions with global regulatory authorities to seek broader authorization for Livdelzi based on the IDEAL study results.

πŸ“… The findings will be presented at The Liver Meeting in Denver from November 5 to 9 and accepted for publication in the Journal of Hepatology.

πŸ’Š Livdelzi currently has accelerated approval in the US but requires confirmatory evidence regarding survival improvement or prevention of liver decompensation.

πŸ“‰ Gilead Sciences stock traded at 147.08 euros on November 6, 2026, representing a 3.93% decline from the previous day's Xetra close.

Bullish Signals
  • Gilead Sciences reported positive Phase 3 IDEAL trial results for Livdelzi in a new patient population with primary biliary cholangitis, achieving a 75.4% response rate at Week 52 compared to 16.1% on placebo.
  • The drug demonstrated an early treatment effect with 52.3% of participants reaching the composite endpoint after just one month versus 6.5% in the placebo group.
  • Livdelzi maintained a favorable safety profile with serious adverse events occurring in only 3.1% of patients on the drug compared to 12.9% on placebo, and no serious adverse events were considered related to the trial drug.
Risk Factors
  • Gilead faces regulatory hurdles as broader use of Livdelzi depends on confirmatory evidence demonstrating survival improvement or prevention of liver decompensation, which has not yet been demonstrated.
  • The company's next step involves regulatory discussions rather than an immediate label expansion, leaving the timing and scope of any broader authorization open.
Full Analysis
Gilead Sciences reported positive Phase 3 IDEAL trial results for its drug Livdelzi in patients with primary biliary cholangitis (PBC) who had lower alkaline phosphatase levels. The study demonstrated that at Week 52, 75.4% of participants receiving Livdelzi achieved the composite endpoint of normalized alkaline phosphatase levels and a significant reduction from baseline, compared to only 16.1% on placebo. The treatment showed an early response, with over half of the patients reaching the primary endpoint after just one month versus 6.5% in the placebo group. The safety profile remained consistent with earlier studies, showing serious adverse events in 3.1% of Livdelzi participants compared to 12.9% on placebo, with none attributed to the trial drug. Gilead plans to engage global regulatory authorities regarding these findings, which will be presented at The Liver Meeting in Denver and published in the Journal of Hepatology. While Livdelzi already holds accelerated approval in the US for specific PBC populations, broader use depends on confirmatory evidence demonstrating survival improvement or prevention of liver decompensation. Following the news, Gilead Sciences stock traded 3.93% below the previous day's Xetra close at 147.08 euros. The company faces a regulatory test to expand the drug's label beyond its current indications, with future developments hinging on discussions with health authorities and the presentation of IDEAL data.